Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.
Clinical trial NCT02292550 · COMPLETED
Trial details
- NCT number
- NCT02292550
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2015-05-14
- Primary completion
- 2018-09-26
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.